# Zura Bio (ZURA) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/ZURA
## Company Profile
- Ticker: ZURA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunology
## Stock Data
- Close: 5.71 USD
- Market cap: 389010910.99999994 USD
- Last updated: 2026-08-06
## Business Overview
### Autoimmune and Inflammatory Diseases
Zura Bio develops biologics for serious autoimmune and inflammatory diseases, emphasizing combinations of validated immune pathways in single molecules.
### Tibulizumab
Tibulizumab is a bispecific antibody designed to neutralize both IL-17 and BAFF. The dual mechanism targets inflammatory and B-cell biology involved in chronic immune-mediated disease.
### TibuSHIELD
TibuSHIELD evaluates tibulizumab in approximately 225 adults with hidradenitis suppurativa, an inflammatory skin disease driven in part by IL-17 signaling.
### TibuSURE
TibuSURE evaluates tibulizumab in approximately 80 adults with systemic sclerosis, where simultaneous IL-17 and BAFF inhibition may address inflammation, autoantibodies and fibrosis.
## Why The Stock Is Moving

As of Aug 6, 2026, ZURA closed up 1.24% at $5.71. No new same-company headline was identified in the current news window.

## Future Catalysts

- Topline Phase 2 TibuSHIELD data in the fourth quarter of 2026.
- Topline Phase 2 TibuSURE data in the first half of 2027.

## Recent News
- 2026-06-29 11:30 EST — [Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program](https://biopharmsignal.com/news/ZURA/zura-bio-exceeds-enrollment-target-in-both-hidradenitis-suppurativa-hs-systemic--cfd7a19d) — Source: Zura Bio
- 2026-05-14 11:30 EST — [Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ZURA/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-6d81197f) — Source: Zura Bio
- 2026-05-13 11:30 EST — [Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer](https://biopharmsignal.com/news/ZURA/zura-bio-expands-leadership-team-with-appointment-of-muzammil-mustufa-as-chief-business-officer) — Source: Zura Bio
- 2026-05-07 11:30 EST — [Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates](https://biopharmsignal.com/news/ZURA/zura-bio-reports-first-quarter-2026-financial-results-and-recent-corporate-updates) — Source: Zura Bio
- 2026-03-19 20:05 EST — [Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates](https://biopharmsignal.com/news/ZURA/zura-bio-reports-full-year-2025-financial-results-and-recent-corporate-updates) — Source: Zura Bio